Harnessing polymer-derived drug delivery systems for combating inflammatory bowel disease

The inflammatory bowel disease (IBD) is incurable, chronic, recrudescent disorders in the inflamed intestines. Current clinic treatments are challenged by systemic exposure-induced severe side effects, inefficiency after long-term treatment, and increased risks of infection and malignancy due to immunosuppression. Fortunately, naturally bioactive small molecules, reactive oxygen species scavengers (or antioxidants), and gut microbiota modulators have emerged as promising candidates for the IBD treatment. Polymeric systems have been engi-neered as a delivery vehicle to improve the bioavailability and efficacy of these therapeutic agents through targeting the mucosa and enhancing intestinal adhesion and retention, and reduce their systemic toxicity. Herein we survey polymer-derived drug delivery systems for combating the IBD. Advanced delivery technologies, therapeutic intervention strategies, and the principles for the construction of hierarchical, mucosa-targeting, and bioresponsive systems are elaborated, providing insights into design and development of from-bench-to-bedside drug delivery polymeric systems for the IBD treatment.

Automated summary

The current clinical treatments for inflammatory bowel disease (IBD) suffer from severe side effects, low long-term treatment efficacy, and increased risks of infection and malignancy. However, naturally bioactive small molecules, reactive oxygen species scavengers, and gut microbiota modulators have emerged as promising candidates for IBD treatment. Polymeric systems have been engineered as delivery vehicles to improve the bioavailability and efficacy of these therapeutic agents, while reducing their systemic toxicity. This article surveys polymer-derived drug delivery systems for combating IBD.